Viking Therapeutics Inc (VKTX)

[DMOST]

Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals
[ACCESSWIRE]
ACCESSWIRE•November 14, 2018

NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed after the company presented data from a Phase 2 trial of VK2809 on Monday.

RDI Initiates Coverage on:

Viking Therapeutics, Inc.
https://www.rdinvesting.com/report/?ticker=VKTX

EyeGate Pharmaceuticals, Inc.
https://www.rdinvesting.com/report/?ticker=EYEG

Viking Therapeutics, Inc. shares closed down a modest 1.71% on Tuesday with nearly 13 million shares traded but saw some of those losses returned in after-hours trading. Earlier this week the company presented results from the Phase 2 trial of VK2809, the company’s thyroid hormone receptor beta (TRß) agonist, in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD) at the 2018 meeting of the American Association for the Study of Liver Diseases (AASLD). "We are very pleased with the safety and efficacy results demonstrated in this trial, which provide us with confidence in VK2809's potential benefit in patients with NAFLD and NASH," stated Brian Lian, Ph.D., CEO of Viking. He added, "The reductions in liver fat, LDL-C, triglycerides and atherogenic proteins suggest a highly differentiated therapeutic profile, which may lead to improved long-term benefits in NASH patients. In addition, the liver safety data from Weeks 12 and 16 suggest improvement in liver health extending beyond the study end, which bodes well for longer-term trials. Based on these exciting results, we are aggressively moving forward with further clinical studies of VK2809 in NASH, which we expect to initiate in 2019."
https://finance.yahoo.com/news/today-research-reports-stocks-watch-115000990.html

GO VKTX

"PEACE"